VolitionRX (VNRX) to Release Quarterly Earnings on Thursday

VolitionRX (NYSEAMERICAN:VNRX) is projected to issue its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.73) per share and revenue of $1.5190 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 8:30 AM ET.

VolitionRX Price Performance

NYSEAMERICAN VNRX opened at $2.32 on Wednesday. VolitionRX has a fifty-two week low of $2.01 and a fifty-two week high of $18.80. The stock’s 50-day moving average is $3.42 and its two-hundred day moving average is $5.07. The firm has a market cap of $18.77 million, a P/E ratio of -0.53 and a beta of 1.03.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on VNRX. HC Wainwright decreased their price objective on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. D. Boral Capital reissued a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. Finally, Citigroup cut shares of VolitionRX to a “hold” rating in a report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $46.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in VolitionRX during the fourth quarter worth $28,000. Virtu Financial LLC lifted its holdings in shares of VolitionRX by 166.6% during the 4th quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock worth $28,000 after acquiring an additional 67,848 shares during the period. Squarepoint Ops LLC bought a new position in shares of VolitionRX during the 4th quarter worth about $34,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of VolitionRX during the 2nd quarter valued at about $52,000. Finally, Citadel Advisors LLC boosted its position in shares of VolitionRX by 70.1% during the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after acquiring an additional 135,775 shares in the last quarter. 8.09% of the stock is owned by institutional investors.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.